Natural 'decoy receptor' protects against inflammatory bowel disease, research reveals

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...
EurekAlert!

Researchers reveal a novel natural “decoy receptor” that protects against inflammatory bowel disease

A research team led by Prof. QIAN Youcun from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences identified a new member of the human IL-17 receptor ...
Chemical Engineering

Crystal Clear: Perfecting Product Purity Through Recrystallization

In the development of new pharmaceutical ingredients and other high-purity products, carefully controlled crystallization ...
eLife

Cross-species evaluation of TANGO2 homologs, including HRG-9 and HRG-10 in Caenorhabditis elegans, challenges a proposed role in heme trafficking

Evidence from multiple model systems supports a shift away from heme transport and toward metabolic dysfunction and oxidative stress as key drivers of TANGO2 deficiency.
The Manila Times

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...
EurekAlert!

Double-fluorescent proteins enable robust maternal haploid identification in wheat

In a paper published on aBIOTECH, the authors developed an efficient haploid identification (HID) system for wheat by ...
The Manila Times

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Therapeutics Inc. ("XORTX" or the "Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
eLife

Separating selection from mutation in antibody language models

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...
Gut

Global guidelines on diverticular disease of the colon: the Fiesole Consensus report

Introduction Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20–25% of affected individuals ...

Idorsia Pharmaceuticals Ltd: Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...
Nature

Damage-associated molecular patterns

Damaged cells produce molecules that trigger inflammation and stimulate the innate or adaptive immune response. These damage-associated molecular patterns, or DAMPs, may be released in response to ...

XORTX Therapeutics Inc.: XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused ...